is an autosomal dominant osteochondrodysplasia characterized by short-limb short stature, brachydactyly and early-onset osteoarthropathy. Typically, at approximately two years of age, the rate of growth falls below the standard growth curve, causing a moderately severe form of disproportionate short-limb short stature. The current study described the clinical and radiographic observations of six Chinese patients with PSACH, and identified two de novo novel missense mutations [p.Asp326Asn (c.976G>A) and c.1585A>G (p.Thr529Ala)] in cartilage oligomeric matrix protein (COMP) in the patients. The current study expanded the mutation spectrum of the COMP gene, and contributes to the understanding of phenotype/genotype of COMP-associated diseases.
Introduction
Pseudoachondroplasia (PSACH; MIM no. 177170) is an autosomal dominant osteochondrodysplasia characterized by short-limb short stature, brachydactyly and early-onset osteoarthropathy (1) . Affected individuals appear normal at birth. A waddling gait is often the presenting feature at the onset of walking (1) . Typically, at approximately two years of age, the rate of growth falls below the standard growth curve, causing a moderately severe form of disproportionate short-limb short stature (1) . Vertebral anomalies, present in childhood, usually resolve with age, however osteoarthritis is progressive and severe.
Previous genetic studies have demonstrated that PSACH is caused by heterozygous mutations in the cartilage oligomeric matrix protein (COMP; MIM no. 600310) gene (2, 3) . COMP is located on chromosome 19p13.1 (4) . COMP rat and bovine sequencing indicate that it is a member of the thrombospondin gene family (4) . It contains 19 exons, encoding the epidermal growth factor-like (type II) repeats, calmodulin-like (type III) repeats and the C-terminal domain. Exons 4-19 correspond in sequence and intron location to the thrombospondin genes, whereas exons 1-3 are unique to COMP (2) .
It is notable that mutations in COMP produce clinical phenotypes ranging from the severe end of the spectrum, PSACH, to a mild condition, multiple epiphyseal dysplasia (MED). Briggs et al (5) suggested that missense mutations in the type III repeats (amino acid residues 268-528) are the major cause of PSACH and MED, exhibit significant phenotypic correlations and derived preliminary genotype to phenotype correlations. However, the correlations remain unclear, and more data is required to further deduce genotype-phenotype correlations. Although numerous mutations in COMP in patients with PSACH have been reported, data on Chinese patients with PSACH remain limited (6) (7) (8) (9) (10) . The current study presents the molecular and clinical characteristics of six Chinese patients with PSACH.
Materials and methods
Patients. The current study was approved by the Ethics Committee of the Sixth People's Hospital Affiliated to Shanghai Jiao Tong University (Shanghai, China). Prior to initiation of the study, written informed consent for genetic tests and publication of the case details was obtained from all adult participants and the parents or the legal guardians on behalf of children involved in the study.
Mutation analysis. Informed consent was obtained from the families and from 250 healthy ethnically matched volunteers prior to blood sampling and DNA analysis. These 250 Chinese volunteers (125 males and 125 females) were recruited from the Department of Osteoporosis, Sixth People's Hospital Affiliated to Shanghai Jiao Tong University. This is the same control cohort used in our previous studies (11, 12) . The DNA was extracted from peripheral white blood cells by proteinase K (Kurabo Industries, Ltd., Tokyo, Japan) digestion followed by purification with phenol/chloroform and isopropyl alcohol precipitation (Ling Feng Chemical Reagent Co., Ltd., Shanghai, China). The DNA sequence for the COMP gene was obtained from the available online database (GenBank accession no. NC_000019). The COMP gene primers (Table I) the BigDye Terminator Cycle Sequencing Ready Reaction kit, version 3.1 (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA), and the sequencing was analyzed with an ABI Prism 3130 automated sequencer (Applier Biosystems; Thermo Fisher Scientific, Inc.). To assess the damaging effects of missense mutations in silico, the online database, Protein Variation Effect Analyzer (PROVEAN; http://provean.jcvi. org/index.php) was used (13) .
Results
Patients. The present study included six Chinese families with PSACH. Detailed clinical information of these families is described in the following sections, and the clinical characteristics are summarized in Table II .
The proband was a 20-year-old male of Han ethnicity. He was the second of two siblings in a healthy non-consanguineous couple. The pregnancy and delivery of this individual were considered normal, and no abnormalities were identified at birth. The patient began to walk at the age of 16 months, and slowness in linear growth was noticed at 5 years of age. Simultaneously, a limp and brachydactyly were noted. Physical examination at the age of 20 years demonstrated disproportional short stature with short limbs: Height, 149 cm (-3 standard deviations); arm span, 137 cm. Generalized brachydactyly of the hands was observed. No restricted extension of the joints was identified, and intelligence was considered normal. The radiographic images presented in Fig 
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view). His parents, brother and relatives were healthy with no similar features observed.
Family 2. The proband was a 5-year-old Han boy. He was the only child of a healthy non-consanguineous couple. The pregnancy and delivery of this individual were considered normal, however no birth parameters were available. Genu varum and slowness in linear growth were noted at the age of 20 months, and the individual began to walk at the age of 2. Physical examination at age of 5 observed disproportional short stature with short limbs: Height, 81 cm (-3 standard deviations); arm span, 78 cm; upper segment/lower segment ratio of 1.57. The hands exhibited generalized brachydactyly and the shoulders and elbows presented with restricted extension. clear genu varum was noted and intelligence was considered normal. The radiographic images presented in Fig The pregnancy and delivery of this individual were considered normal, however no birth parameters were available Genu varum and slowness in linear growth were noted at the age of 2. Physical examination demonstrated disproportional short stature with short limbs: Height, 84 cm (-3 standard deviations); arm span, 83 cm; upper segment/lower segment ratio, 1.51. Moderate generalized brachydactyly of the hand was observed and extension of the shoulders and elbows was restricted. He additionally presented with pectus carinatum.
His intelligence was normal. The radiographic images presented in Fig. 1F exhibited clinical features of PSACH disease. The patient had similar radiographic characteristics to that of patient 2. His parents and relatives were healthy with no similar features.
Sequence analysis. Screening was conducted for mutations in COMP in all patients and their parents using PCR followed by direct sequence analysis. The sequencing identified that five patients carried heterozygous missense mutations of COMP and one carried a heterozygous in-frame deletion in exon 13 of COMP: c.772G>C (p.Gly258Arg) in exon 8 of patient 1 (Fig. 2A) , c.1585A>G (p.Thr529Ala) in exon 14 of patient 2 (Fig. 2B ), c.976G>A (p.Asp326Asn) in exon 10 of patient 3 (Fig. 2C ), c.1417_1419delGAC (p.Asp473del) in exon 13 of patient 4 (Fig. 2D ), c.812A>T (p.Asp271Val) in exon 8 of patient 5 (Fig. 2E) , and c.1512C>G (p.Cys504Trp) in exon 14 of patient 6 (Fig. 2F ). Based on DNA sequence analysis, all the mutations were de novo, and were not identified in DNA samples from healthy parents and 250 healthy volunteers. Among these mutations, c.976G>A (p.Asp326Asn) and c.1585A>G (p.Thr529Ala) are, to the best of our knowledge, novel. p.Asp326Asn and p.Thr529Ala were non-conservative, evolutionarily highly conserved amino acids from fish to mammals ( Fig. 3A and B) , and were predicted in silico by PROVEAN to be of pathogenic relevance (p.Asp326Asn, PROVEAN score of -4.542; p.Thr529Ala, PROVEAN score of -4.610).
Discussion
Although PSACH is an unambiguous skeletal dysplasia easily diagnosed by physicians, two major entities should be considered in the differential diagnosis. Firstly, the body proportions of patients with PSACH resemble those of patients with achondroplasia at the second year of life or later. However, patients with PSACH appear normal at birth and their faces are normal, while the characteristics of achondroplasia are recognized at birth with characteristic frontal bossing (14) . In addition, there is gradual narrowing of the lumbar interpedicular distances in the lower lumbar spine in achondroplasia, which is absent in PSACH. Secondly, mucopolysaccharidosis IV, also termed Morquio syndrome, may be confused with PSACH, due to the fact that both disorders present with anterior beaking of the vertebral bodies (15) . However, the anterior beaking of the vertebral bodies is seen exclusively during childhood in patients with PSACH, and resolves with age. In addition, pointed proximal 2nd, 3rd, 4th and 5th metacarpals, which are unique to mucopolysaccharidosis IV, are not observed in PSACH. Mucopolysaccharide analysis of urine will confirm diagnosis. Mutation analysis is, however, a simple way of confirming the diagnosis of PSACH. Previous ultrastructural studies on cartilage from patients with PSACH demonstrated abnormal accumulation of electron-dense and light material within the chondrocyte rough endoplasmic reticulum (16, 17) . Biochemical and histochemical studies have additionally suggested that PSACH was a generalized cartilage disorder involving abnormalities of proteoglycans (18, 19) . Cartilage consists of chondrocytes and abundant extracellular matrix components including glycoproteins, aggrecans and collagens. COMP is a pentameric glycoprotein of the cartilage extracellular matrix that is localized predominantly to the territorial matrix surrounding the chondrocytes. In vitro studies have reported that chondrocyte-specific intracellular trafficking defects were observed for the p.Asp469del mutant COMP (20, 21) . Furthermore, different COMP mutations in the type 3 repeat domain have been identified to produce variable effects on intracellular transport, which correlate with clinical severity (22) . Mutations in COMP have additionally been reported to affect the secretion of type IX collagen and matrilin 3, however not the secretion of aggrecan and type II collagen (23) . Furthermore, a recent study using the COMP p.Asp469del mutant mouse model suggested that chondrocyte stress triggered by the expression of mutant COMP was central to the pathogenesis of PSACH (24) .
The key observation of the present study was the identification of two novel mutations in COMP: c.976G>A (p.Asp326Asn) and c.1585A>G (p.Thr529Ala). Notably, previous studies reported that p.Asp326Tyr resulted in PSACH while p.Asp326Gly led to MED (25, 26) . In the current study, p.Asp326Asn in COMP was observed to result in a PSACH phenotype in a Chinese girl. This patient manifested with severe epiphyseal deformities and clear delay in linear growth. Furthermore, the radiographic images indicated clear platyspondyly and anterior beaking of the vertebral bodies. These features can help differentiate between PSACH from MED. It is suggested that different substitutions at the same residue of p.Asp326 lead to different phenotypes. It is also possible that genetic modifiers of phenotypic severity are likely to influence disease severity (5) . This data may be useful for further analysis of correlations between genotype and phenotype. In addition, a notable hotspot, c.1417_1419delGAC (p.Asp473del), was identified. This mutation had been previously reported in 49 cases of PSACH and was identified as the most common mutation (1). In summary, the current study reported the molecular and clinical observations of six Chinese patients with PSACH. Two novel mutations in the COMP gene were identified. The present study expanded upon the mutation spectrum in the COMP gene, and contributed to the understanding of the phenotype/genotype of COMP-associated diseases.
